Similar articles for PMID: 19732174

Year	Number of Results
2001	1
2002	4
2003	1
2004	5
2005	8
2006	5
2007	6
2008	18
2009	24
2010	19
2011	12
2012	13
2013	20
2014	7
2015	8
2016	8
2017	6
2018	4
2019	5
2020	3
2021	2
2022	4
2024	0

1

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

Scherrer AU, Hasse B, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Bucher HC, Ledergerber B, Günthard HF. Scherrer AU, et al. HIV Med. 2009 Nov;10(10):647-56. doi: 10.1111/j.1468-1293.2009.00756.x. Epub 2009 Sep 1. HIV Med. 2009. PMID: 19732174 Free article.

2

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.

Cotte L, Trabaud MA, Tardy JC, Brochier C, Gilibert RP, Miailhes P, Trépo C, André P. Cotte L, et al. J Med Virol. 2009 Apr;81(4):672-7. doi: 10.1002/jmv.21461. J Med Virol. 2009. PMID: 19235860

3

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group. Bannister WP, et al. AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35. AIDS. 2008. PMID: 18195563

4

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group. Cabrera C, et al. Antivir Ther. 2004 Oct;9(5):787-800. Antivir Ther. 2004. PMID: 15535417

5

Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C. Lapadula G, et al. Antivir Ther. 2008;13(4):601-5. Antivir Ther. 2008. PMID: 18672539

6

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.

Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network. Anta L, et al. AIDS. 2013 Jan 2;27(1):81-5. doi: 10.1097/QAD.0b013e3283584500. AIDS. 2013. PMID: 22842995

7

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team. Puthanakit T, et al. HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25. HIV Med. 2010. PMID: 20345882 Free article.

8

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G. Vingerhoets J, et al. Antivir Ther. 2013;18(2):253-6. doi: 10.3851/IMP2358. Epub 2012 Sep 6. Antivir Ther. 2013. PMID: 22951490 Clinical Trial.

9

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B. Llibre JM, et al. J Antimicrob Chemother. 2008 Nov;62(5):909-13. doi: 10.1093/jac/dkn297. Epub 2008 Jul 23. J Antimicrob Chemother. 2008. PMID: 18653487

10

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group. Marcelin AG, et al. Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886. Antivir Ther. 2012. PMID: 22267476

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

170 results

Results by year